Figure 4.
Predicted oral (PO) and intravenous (IV) tacrolimus dose ratios following PO and IV administration of the CYP3A inhibitor itraconazole in donors, recipients and both donors and recipients expressing CYP3A5 (*1/*1).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.